Literature DB >> 14966085

NF-kappa B in the vascular progression of melanoma.

Mohammed Kashani-Sabet1, Ladan Shaikh, James R Miller, Mehdi Nosrati, Carlos M M Ferreira, Robert J Debs, Richard W Sagebiel.   

Abstract

PURPOSE: To examine a model of melanoma progression based on vascular factors and the role of NF-kappa B in the vascular progression of melanoma. PATIENTS AND METHODS: A data set of 526 patients from the University of California San Francisco Melanoma Center with 2 years of follow-up or first relapse was studied. The impact of the presence or absence of various prognostic factors on overall survival of melanoma patients was assessed using Cox regression and Kaplan-Meier analysis. A matched-pair analysis of NF-kappa B expression was performed in cases with vascular involvement and increased tumor vascularity versus matched controls lacking these factors.
RESULTS: Cox regression analysis of factors evaluated by the American Joint Committee on Cancer Melanoma Staging Committee reproduced the powerful impact of tumor thickness and ulceration in this data set. With the inclusion of vascular factors such as tumor vascularity and vascular involvement, ulceration was no longer significant in predicting overall survival. By multivariate analysis, vascular involvement and tumor vascularity were the strongest predictors of melanoma outcome. Tumor vascularity seems to be a precursor of both vascular involvement and ulceration. A matched-pair tissue array analysis demonstrated the significant correlation between overexpression of NF-kappa B-p65 and the development of vascular factors.
CONCLUSION: Vascular factors play an important role in the progression of malignant melanoma. Ulceration may be a surrogate marker for the interactions between melanoma and the tumor vasculature. NF-kappa B seems to play an important role in the development of these factors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14966085     DOI: 10.1200/JCO.2004.06.047

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  19 in total

1.  Inhibitory effect and mechanism of mesenchymal stem cells on melanoma cells.

Authors:  J Zhang; L Hou; D Zhao; M Pan; Z Wang; H Hu; J He
Journal:  Clin Transl Oncol       Date:  2017-07-21       Impact factor: 3.405

2.  Nuclear heparanase-1 activity suppresses melanoma progression via its DNA-binding affinity.

Authors:  Y Yang; C Gorzelanny; A T Bauer; N Halter; D Komljenovic; T Bäuerle; L Borsig; M Roblek; S W Schneider
Journal:  Oncogene       Date:  2015-03-09       Impact factor: 9.867

Review 3.  Inflammation and cancer: how friendly is the relationship for cancer patients?

Authors:  Bharat B Aggarwal; Prashasnika Gehlot
Journal:  Curr Opin Pharmacol       Date:  2009-08-06       Impact factor: 5.547

4.  Epigenetic Regulation of KPC1 Ubiquitin Ligase Affects the NF-κB Pathway in Melanoma.

Authors:  Yuuki Iida; Aaron Ciechanover; Diego M Marzese; Keisuke Hata; Matias Bustos; Shigeshi Ono; Jinhua Wang; Matthew P Salomon; Kevin Tran; Stella Lam; Sandy Hsu; Nellie Nelson; Yelena Kravtsova-Ivantsiv; Gordon B Mills; Michael A Davies; Dave S B Hoon
Journal:  Clin Cancer Res       Date:  2017-04-07       Impact factor: 12.531

5.  Pleckstrin homology domain-interacting protein (PHIP) as a marker and mediator of melanoma metastasis.

Authors:  David De Semir; Mehdi Nosrati; Vladimir Bezrookove; Altaf A Dar; Scot Federman; Geraldine Bienvenu; Suraj Venna; Javier Rangel; Joan Climent; Tanja M Meyer Tamgüney; Suresh Thummala; Schuyler Tong; Stanley P L Leong; Chris Haqq; Paul Billings; James R Miller; Richard W Sagebiel; Robert Debs; Mohammed Kashani-Sabet
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-17       Impact factor: 11.205

6.  A multimarker prognostic assay for primary cutaneous melanoma.

Authors:  Mohammed Kashani-Sabet; Suraj Venna; Mehdi Nosrati; Javier Rangel; Antje Sucker; Friederike Egberts; Frederick L Baehner; Jeff Simko; Stanley P L Leong; Chris Haqq; Axel Hauschild; Dirk Schadendorf; James R Miller; Richard W Sagebiel
Journal:  Clin Cancer Res       Date:  2009-11-03       Impact factor: 12.531

7.  Nuclear factor-κB expression is predictive of overall survival in patients with cutaneous melanoma.

Authors:  Daniela Murtas; Franca Piras; Luigi Minerba; Jorge Ugalde; Michela Piga; Cristina Maxia; Maria Teresa Perra; Paola Sirigu
Journal:  Oncol Lett       Date:  2010-07-01       Impact factor: 2.967

Review 8.  EZH2 as a mediator of treatment resistance in melanoma.

Authors:  Jessamy C Tiffen; Stuart J Gallagher; Hsin-Yi Tseng; Fabian V Filipp; Barbara Fazekas de St. Groth; Peter Hersey
Journal:  Pigment Cell Melanoma Res       Date:  2016-05-25       Impact factor: 4.693

9.  Semaphorin 3E expression correlates inversely with Plexin D1 during tumor progression.

Authors:  Ilse Roodink; Gürsah Kats; Léon van Kempen; Meritha Grunberg; Cathy Maass; Kiek Verrijp; Jos Raats; William Leenders
Journal:  Am J Pathol       Date:  2008-10-30       Impact factor: 4.307

10.  A multi-marker assay to distinguish malignant melanomas from benign nevi.

Authors:  Mohammed Kashani-Sabet; Javier Rangel; Sima Torabian; Mehdi Nosrati; Jeff Simko; David M Jablons; Dan H Moore; Chris Haqq; James R Miller; Richard W Sagebiel
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-30       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.